Related references
Note: Only part of the references are listed.Shifting paradigms in the treatment of older adults with AML
Thomas W. LeBlanc et al.
SEMINARS IN HEMATOLOGY (2019)
Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia
Kent T. J. Chen et al.
PHARMACEUTICAL RESEARCH (2019)
Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads
Jayesh A. Kulkarni et al.
NANOSCALE (2019)
Is the overall survival for older adults with AML finally improving?
Jeffrey E. Lancet
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems in vivo
Sandro Sieber et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Andrew H. Wei et al.
BLOOD (2017)
The protein corona of circulating PEGylated liposomes
Sara Palchetti et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2016)
PRCosomes: pretty reactive complexes formed in liposomes
Mohamed Wehbe et al.
JOURNAL OF DRUG TARGETING (2016)
Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development
Mohamed Wehbe et al.
PLOS ONE (2016)
The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia
Steven Knapper
HAEMATOLOGICA (2015)
Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia
Joshua F. Zeidner et al.
LEUKEMIA RESEARCH (2015)
Formation of lipid and polymer based gold nanohybrids using a nanoreactor approach
Dominik Witzigmann et al.
RSC ADVANCES (2015)
The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia
Steven Knapper
HAEMATOLOGICA (2015)
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Nestor R. Ramos et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia
M-P Garcia-Cuellar et al.
LEUKEMIA (2014)
Liposomal drug delivery systems: From concept to clinical applications
Theresa M. Allen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Jia Ji et al.
CLINICAL CANCER RESEARCH (2013)
Acute myeloid leukaemia in adults
Felicetto Ferrara et al.
LANCET (2013)
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Eric J. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
K. A. Blum et al.
LEUKEMIA (2011)
The Binding of Flavopiridol to Blood Serum Albumin
Daniel Myatt et al.
CHIRALITY (2010)
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
William Blum et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
A novel liposomal formulation of flavopiridol
Xiaojuan Yang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Acute Myelogenous Leukemia in Older Adults
Heidi D. Klepin et al.
ONCOLOGIST (2009)
A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention
Euan Ramsay et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2008)
Flavopiridol displays preclinical activity in acute lymphoblastic leukemia
Kelly M. Jackman et al.
PEDIATRIC BLOOD & CANCER (2008)
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding
Nancy Dos Santos et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2007)
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity
IW Flinn et al.
LEUKEMIA RESEARCH (2005)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
R Chen et al.
BLOOD (2005)
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
S Burdette-Radoux et al.
INVESTIGATIONAL NEW DRUGS (2004)
Flavopiridol, an inhibitor of transcription - Implications, problems and solutions
MV Blagosklonny
CELL CYCLE (2004)
Phase II study of flavopiridol in patients with advanced colorectal cancer
M Aklilu et al.
ANNALS OF ONCOLOGY (2003)
Flavonoid effects on normal and leukemic cells
JL Liesveld et al.
LEUKEMIA RESEARCH (2003)
Formation of transition metall-doxorubicin complexes inside liposomes
SA Abraham et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2002)
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
GK Schwartz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase
A Kaiser et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2001)
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status
LR Kelland
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
Share Paper
